[1] Pholwat S, Heysell S, Stroup S, et al.Rapid first- and second-line drug susceptibility assay for Mycobacterium tuberculosis isolates by use of quantitative PCR. J Clin Microbiol,2011,49(1): 69-75.
[2] 叶任高,陆再英,谢毅,等. 内科学. 6版.北京:人民卫生出版社,2004:15-56.
[3] Tostmann A, Boeree MJ, Peters WH, et al.Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int J Antimicrob Agents,2008, 31(6): 577-580.
[4] Yew WW, Leung CC. Antituberculosis drugs and hepatotoxi-city. Am J Respir Crit Care Med, 2007,175(8): 858-859.
[5] Chang KC,Leung CC,Yew WW,et al.Hepatotoxicity of pyra-zinamide: cohort and case-control analyses. Am J Respir Crit Care Med, 2008,177(12): 1391-1396.
[6] Chang KC,Leung CC. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate. Clin Infect Dis,2010,51(3): 366-368.
[7] Saigal S, Agarwal SR, Nandeesh HP, et al. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. J Gastroenterol Hepatol,2001,16(9): 1028-1032.
[8] 周应初,刘斌.抗结核药致肝损害的研究现状. 国际病理科学与临床杂志,2011,31(4):361-365.
[9] Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol, 2008,23(2): 192-202.
[10] Tostmann A, Boeree MJ, Peters WH, et al. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. Int J Antimicrob Agents,2008,31(6): 577-580.
[11] Bose PD, Sarma MP, Medhi S, et al. Role of polymorphic N-acetyl transferase2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol,2011,26(2):312-318.
[12] 安慧茹,吴雪琼.抗结核药物性肝损害研究进展.中国抗生素杂志,2010,35(10):727-733.
[13] Sarich TC, Adams SP, Zhou T, et al. Isoniazid-induced hepatic necrosis and steatosis in rabbits: absence of effect of gender. Can J Physiol Pharmacol,1997,75(9):1108-1111.
[14] Kobayashi M, Otani T, Iwasaki M, et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2,CYP1A1,and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan. Gastric Cancer,2009,12(4):198-205.
[15] Vuilleumier N, Rossier MF, Chiappe A, et al. CYP2E1 genotype and isoniazid -induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol,2006,62(6):423-429.
[16] Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by po-lymerase chain reaction in American whites and blacks. Pharmacogenetics,1996,6(2):187-191.
[17] Butler MW,Hackett NR,Salit J,et al. Glutathione S-transfe-rase copy number variation alters lung gene expression. Eur Respir J,2011,38(1):15-28.
[18] Strange RC,Spiteri MA,Ramachandran S,et al.Glutathione-S-transferase family of enzymes. Mutat Res,2001,482(1/2): 21-26.
[19] Sindi SS, Raphael BJ. Identification and frequency estimation of inversion polymorphisms from haplotype data. J Comput Biol,2010,17(3): 517-531.
[20] Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis, 2000,4(3): 256-261.
[21] Fountain FF, Tolley EA, Jacobs AR, et al. Rifampin hepatotoxicity associated with treatment of latent tuberculosis infection. Am J Med Sci,2009, 337(5): 317-320.
[22] Pholwat S, Heysell S, Stroup S, et al. Rapid first- and se-cond-line drug susceptibility assay for Mycobacterium tuberculosis isolates by use of quantitative PCR. J Clin Microbiol,2011,49(1):69-75.
[23] Ueda K, Ishitsu T, Seo T, et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics,2007,8(5):435-442.
[24] Usui T, Hashizume T, Katsumata T, et al. In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug Metab Dispos,2011,39(7):1303-1310.
[25] Roy B,Chowdhury A,Kundu S, et al. Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 ‘null’ mutation. J Gastroenterol Hepatol,2001,16(9): 1033-1037.
[26] Huang YS, Su WJ, Huang YH, et al. Genetic polymorphisms of manganese superoxide dismutase,NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol, 2007,47(1):128-134.
[27] Leiro V, Fernández-Villar A, Valverde D, et al. Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int,2008,28(6): 835-839.
[28] Thoudam RD, Yadav DS, Mishra AK,et al. Distribution of glutathione S-transferase T1 and M1 genes polymorphisms in North East Indians: a potential report. Genet Test Mol Biomarkers,2010,14(2):163-169.
[29] Chatterjee S, Lyle N, Mandal A, et al. GSTT1 and GSTM1 gene deletions are not associated with hepatotoxicity caused by antitubercular drugs. J Clin Pharm Ther,2010,35(4): 465-470. |
京公安网备11010202008787号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
